Neuro-Bio Company Board Members And Brief Synopsis

BOARD

Baroness Professor Susan Greenfield, CBE

CEO and Founder

Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist and has published over 200 papers in peer-reviewed journals over the course of her 40-year career, based mainly at Oxford University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.

Dr Michal Zurawski

Chairman Desiginate

Michal is CEO of a pre-clinical UK-based biotechnology company: MICA Biosystems. He is Venture Capitalist at a Life Sciences Specialist, London based Family Office. He holds a PhD in orthopaedic biotech at the University of Nottingham in partnership with a global biotech firm – Zimmer Biomet. He is a British Army Reservist since 2016.

David Fuente

Investor Director

Dave is the former chairman and CEO of Office Depot and former president of Sherwin-Williams Paint Stores. In addition to his role as Chairman Emeritus of SSA & Company, he is a Senior Advisor at Peter J. Solomon Company. He formerly served on the boards of Office Depot, Ryder Transportation, Dicks Sporting Good and others. Dave was appointed on the board by Kairos Ventures as an Investor Director for Neuro-Bio.

Todd Thomson

Kairos Ventures

Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5
years and as CEO of Citigroup’s $10 Billion Global Wealth Management division for 2.5 years. Todd is a
leading practitioner on M&A and business strategy, having led the acquisition and strategy efforts for
Citigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz
Allen Hamilton, and Barents Group.

At Kairos, Todd oversees all operational and financial aspects of the firm and serves on the Kairos
Investment Committee. Kairos has partnered closely with 16 prominent universities to select and
commercialize their most ground-breaking patented innovations in life sciences and physical sciences.

Todd received his MBA, with Distinction, from the Wharton School of Business and his BA in Economics
from Davidson College.

Professor Herrling

Non-Executive Director

Professor Paul Herrling was Head of Corporate Research at Novartis. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore, an endeavour to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding. Prior to this, Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC), he is a member of the Board of the Genomics Institute of the Novartis Research Foundation in La Jolla California and he serves on the boards of several other research institutions. Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA).

Watch Professor Herrling contribute to the Press Conference held on the 5th of April 2022 at the Royal College of Physicians

T: +44 (0)1235 420 085
E: info@neuro-bio.com